You are here: Industry Insights > Investment

News List

Boehringer Ingelheim Ups Venture Fund to €250M biospace
January 04, 2018
Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M€
Cambridge-Based Aura Biosciences Scoops Up $30M biospace
December 26, 2017
Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it closed a $30 million Series C financing.
NovaBay Pharmaceuticals Receives Stockholder Approval for Proposed $10.32 Million Financing Agreemen biospace
December 25, 2017
NovaBay Pharmaceuticals (NYSE: NBY) Announces Shareholders' Approval of Issuance of NovaBay Common Shares as part of a $ 10.32M facility agreement with Gemstone Capital (Beijing) Co., Ltd.
Pionyr Immunotherapeutics gains meaty $62M series B fiercebiotech
December 14, 2017
California startup Pionyr is using $62 million of VC-backed funding to target antibodies in the tumor microenvironment.
UK Government commits £210M to grow Life Science Sector biospectrumasia
December 11, 2017
Government has committed up to £210 million ($280.9 million) to expand early diagnostics programs, genomics research, and artificial intelligence-driven science
GSK to invest £40m in UK's life sciences sector pharmaceutical-business-review
December 08, 2017
GlaxoSmithKline (GSK) has agreed to invest £40m in genetic research as part of the UK Government’s life sciences sector deal.
Cambridge Biotech Obsidian Launches With $49.5M Investment From Google, Takeda, Vertex, Amgen, Ot biospace
December 07, 2017
Obsidian Therapeutics officially launched with the completion of a Series A financing worth $49.5 million.
The UK Government announces major life sciences venture as it unveils its industrial strategy biospectrumasia
November 28, 2017
The UK’s business department has secured a major multi-million pound investment with a leading Life Sciences firm, MSD, known as Merck and co. in North America.
Michigan third most preferred destination in Midwest for life science investment biospectrumasia
September 12, 2017
Michigan third most preferred destination in Midwest for life science investment Michigan ranked behind Ohio, with US $293.7 million in 55 deals, and regional leader Minnesota, with US $337 million in 59 investments.
Vaccine market expected to grow at a CAGR of 7.5% by 2022 pharmaasia
August 29, 2017
The vaccine market is forecast to reach US$49.27 billion by 2022 at a CAGR of 7.5% from US$34.30 billion in 2017.

Previous page 1 2 3 4 5 6 7 8 Next page